IDXX:NASDAQ
IDEXX Laboratories Inc
$509.40
arrow_downward
-1.17%(-6.01) 1D
Oct 7, 1:09:52 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IDXX...
Open
$513.31
High
$515.17
Low
$501.17
Mkt. cap
40.13B
Avg. vol.
483.24K
Volume
265.14K
P/E ratio
35.80
52-wk high
$769.98
52-wk low
$500.61
EPS
$14.23
Beta
1.55
Shares outstanding
78.78M
No. of employees
11K
Open
$513.31
High
$515.17
Low
$501.17
Mkt. cap
40.13B
Avg. vol.
483.24K
Volume
265.14K
P/E ratio
35.80
52-wk high
$769.98
52-wk low
$500.61
EPS
$14.23
Beta
1.55
Shares outstanding
78.78M
No. of employees
11K
News stories
From web sources and news partners
AD HOC NEWS
·
13 hours ago
IDEXX Laboratories stock fell 2.21 percent on October 6
AD HOC NEWS
·
16 hours ago
IDEXX Laboratories acquires CoVetAI: what it means for IDEXX Laboratories stock
News Corp
·
20 hours ago
IDEXX Laboratories Inc. stock underperforms Tuesday when compared to competitors
AD HOC NEWS
·
1 day ago
Analysts keep Moderate Buy on IDEXX Laboratories stock
Profile
IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets. Incorporated in 1983 by David Evans Shaw, the company is headquartered in Westbrook, Maine, and in Hoofddorp, Netherlands for its EMEA divisions. IDEXX offers products to customers in over 175 countries around the world and employs about 11,000 people in full-and part-time positions.
In 2002, Jon Ayers succeeded company founder Shaw as chairman and CEO. During Ayers 20-year tenure, the company's annual revenue grew from $380 million to $3 billion, raising share prices by more than 100 times. In 2019, Jay Mazelsky succeeded Ayers in the role of CEO.
In 2025, IDEXX estimated annual sales between $4.21 billion and $4.28 billion, with total quarterly revenue exceeding $1 billion. Wikipedia
About IDEXX Laboratories Inc
CEOJay Mazelsky
Employees11K
FoundedDec 19, 1983
HeadquartersWestbrook, Maine, United States
SectorMedical device
Websiteidexx.com
Analyst ratings
Based on 7 analysts giving stock ratings to IDXX in the past 3 months
Buy
Buy
4
Hold
3
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for IDXX in the last 3 months.
Highest
Current $509.40
$805.00 (+58.03%)
Average
$699.17 (+37.25%)
Lowest
$665.00 (+30.55%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Ryan Daniels William Blair | Buy | Maintained | - | - | 10/02/2026 |
Andrea Alfonso UBS | Hold | Reiterated | $670.00 | +31.5% | 09/16/2026 |
Michael Ryskin Bank of America Securities | Hold | Maintained | $665.00 | +30.5% | 08/14/2026 |
Jonathan Block Stifel Nicolaus | Buy | Reiterated | $675.00 | +32.5% | 08/14/2026 |
Glen Santangelo Barclays | Buy | Maintained | $710.00 | +39.4% | 08/11/2026 |
Erin Wright Morgan Stanley | Buy | Maintained | $805.00 | +58% | 08/05/2026 |
Daniel Grosslight Citi | Hold | Maintained | $670.00 | +31.5% | 08/05/2026 |
Keith Devas Jefferies | Buy | Reiterated | $792.00 | +55.5% | 05/06/2026 |
Unknown Analyst Jefferies | Buy | Reiterated | $729.00 | +43.1% | 05/06/2026 |
David Westenberg Piper Sandler | Hold | Maintained | $750.00 | +47.2% | 02/09/2026 |
Mark Massaro BTIG | Buy | Reiterated | $800.00 | +57% | 02/03/2026 |
Last report
Aug 4, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$4.27 / $3.93
+8.54%beat
arrow_upward
Revenue / Est. (USD)
1.22B / 1.20B
+1.35%beat
arrow_upward
Fiscal Q2 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 1.11B | 1.09B | 1.14B | 1.22B |
Cost of goods sold | 421.88M | 432.46M | 418.08M | 437.50M |
Cost of revenue | 421.88M | 432.46M | 418.08M | 437.50M |
Research and development expenses | 63.42M | 66.83M | 65.79M | 65.43M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 265.09M | 266.68M | 294.36M | 288.09M |
Operating expense | 328.51M | 333.51M | 360.15M | 353.52M |
Total operating expenses | 750.39M | 765.97M | 778.23M | 791.02M |
Operating income | 354.85M | 324.60M | 362.59M | 425.57M |
Other non operating income | - | - | - | - |
EBT including unusual items | 344.77M | 306.98M | 355.44M | 417.22M |
EBT excluding unusual items | 344.77M | 315.98M | 355.44M | 415.99M |
Income tax expense | 70.16M | 58.79M | 77.00M | 78.81M |
Effective tax rate | 20.35% | 19.15% | 21.66% | 18.89% |
Other operating expenses | - | - | - | - |
Net income | 274.61M | 248.19M | 278.45M | 338.41M |
Net profit margin | 24.85% | 22.76% | 24.41% | 27.82% |
Earnings per share | 3.40 | 3.08 | 3.47 | 4.27 |
Interest and investment income | 580.00K | 587.00K | 597.00K | 606.00K |
Interest expense | -10.66M | -9.21M | -7.74M | -10.18M |
Net interest expenses | -10.08M | -8.62M | -7.14M | -9.58M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 391.47M | 363.33M | 400.27M | 466.62M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1